Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.66 HKD | -3.94% | -.--% | -50.47% |
04-08 | JenaValve Technology, Inc. announced that it has received $100.4 million in funding from a group of investors | CI |
04-02 | Peijia Medical Limited Delays in Publication of 2023 Annual Results | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's share price in relation to its net book value makes it look relatively cheap.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-50.47% | 316M | - | ||
-7.58% | 10.74B | A- | ||
+2.17% | 8.93B | C | ||
+22.75% | 7.61B | C | ||
+33.99% | 5.27B | B+ | ||
+8.12% | 3.42B | C- | ||
-8.48% | 2.86B | B- | ||
-5.07% | 2.23B | - | - | |
-4.22% | 2.13B | - | ||
-20.87% | 1.84B | - | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- 9996 Stock
- Ratings Peijia Medical Limited